First Trust Advisors’s Viridian Therapeutics VRDN Stock Holding History

First Trust Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.33M	Sell	181,234 -120,295	-40%	-$1.94M	﹤0.01%	1783
2026 Q1	$5.9M	Buy	301,529 +181,637	+152%	+$5.39M	﹤0.01%	1347
2025 Q4	$3.73M	Buy	+119,892	New	+$3.29M	﹤0.01%	1576
2023 Q3	–	Sell	-11,992	Closed	-$285K	–	2500
2023 Q2	$285K	Buy	+11,992	New	+$308K	﹤0.01%	2249

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

First Trust Advisors's VRDN Position: Q2 2026 in Review

First Trust Advisors reduced its Viridian Therapeutics (VRDN) stake by 40% in Q2 2026, selling an estimated $1.94M and leaving 181,234 shares worth $3.33M. The position accounts for ﹤0.01% of the portfolio, ranked #1783.

First Trust Advisors first reported a position in VRDN in Q2 2023 and has held it in 4 quarters since. The position peaked at $5.9M in Q1 2026. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

First Trust Advisors held 181,234 shares of Viridian Therapeutics worth $3.33M as of Q2 2026.
First Trust Advisors sold 120,295 Viridian Therapeutics shares in Q2 2026, an estimated $1.94M.
Viridian Therapeutics made up ﹤0.01% of First Trust Advisors's portfolio in Q2 2026, its #1783 holding.
First Trust Advisors first reported a position in Viridian Therapeutics in Q2 2023 and has held it in 4 quarters since.
First Trust Advisors's Viridian Therapeutics position peaked at $5.9M in Q1 2026.
215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.